We found that D-gal treatment induced noticeably aging-related changes, including cognitive impairment and memory deficits; decrease in swimming time in the weight-loaded swimming test and thymus coefficient; increase in senescence-associated β-galactosidase (SA-β-gal) activity; p16, p19, p21, interleukin- (IL-) 1β and IL-6 gene expression; and oxidative stress in the liver, spleen, and brain. Here, CDKN2A is linked to Cognitive impairment.